Acrivon Therapeutics (NASDAQ:ACRV) CEO Peter Blume-Jensen Sells 14,036 Shares of Stock

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) CEO Peter Blume-Jensen sold 14,036 shares of Acrivon Therapeutics stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total transaction of $31,019.56. Following the transaction, the chief executive officer directly owned 2,230,052 shares in the company, valued at approximately $4,928,414.92. This represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peter Blume-Jensen also recently made the following trade(s):

• On Tuesday, August 18th, Peter Blume-Jensen sold 484 shares of Acrivon Therapeutics stock. The shares were sold at an average price of $2.01, for a total transaction of $972.84.
• On Tuesday, August 18th, Peter Blume-Jensen sold 1,229 shares of Acrivon Therapeutics stock. The shares were sold at an average price of $2.01, for a total transaction of $2,470.29.

Acrivon Therapeutics Stock Up 3.4%

Acrivon Therapeutics stock traded up $0.07 during mid-day trading on Thursday, hitting $2.15. 188,254 shares of the company’s stock were exchanged, compared to its average volume of 975,386. The company’s 50 day simple moving average is $1.79 and its 200-day simple moving average is $1.70. The firm has a market capitalization of $92.13 million, a P/E ratio of -1.14 and a beta of 1.85. Acrivon Therapeutics, Inc. has a fifty-two week low of $1.27 and a fifty-two week high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.07. Research analysts expect that Acrivon Therapeutics, Inc. will post -1.8 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ACRV. Focus Partners Wealth acquired a new stake in Acrivon Therapeutics in the 3rd quarter valued at approximately $36,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Acrivon Therapeutics during the 4th quarter worth approximately $40,000. Vermillion & White Wealth Management Group LLC bought a new position in shares of Acrivon Therapeutics during the 4th quarter worth approximately $44,000. Quadrature Capital Ltd acquired a new stake in shares of Acrivon Therapeutics in the fourth quarter valued at approximately $50,000. Finally, Invesco Ltd. bought a new stake in shares of Acrivon Therapeutics in the first quarter worth $72,000. 71.62% of the stock is owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.